Wells Fargo analyst Brandon Couillard has downgraded Waters (WAT) price target from $415 to $355, while maintaining an “Equal-Weight” rating. This follows similar price target reductions by B of A Securities and UBS, though Guggenheim and HSBC initiated or reiterated “Buy” ratings with higher price targets. Waters is a manufacturer of liquid chromatography, mass spectrometry, and thermal analysis tools, with plans to merge with BD’s life science and diagnostics business.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Waters (WAT) Sees Price Target Downgrade by Wells Fargo | WAT St
Wells Fargo analyst Brandon Couillard has downgraded Waters (WAT) price target from $415 to $355, while maintaining an “Equal-Weight” rating. This follows similar price target reductions by B of A Securities and UBS, though Guggenheim and HSBC initiated or reiterated “Buy” ratings with higher price targets. Waters is a manufacturer of liquid chromatography, mass spectrometry, and thermal analysis tools, with plans to merge with BD’s life science and diagnostics business.